DLBCL follow-up after returning home: surveillance, recovery and handover

Follow-up after DLBCL treatment in China begins with a clear treatment conclusion and a working handover. The patient needs to know whether the entire course is complete, what the last assessment showed, which toxicities remain and whether medicines or cellular-therapy observation continue. Leaving the hospital is not the same as finishing all medical care. [S1,S12]

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The summary should specify final pathology, baseline stage, actual regimen and doses, completion date, final imaging and the response conclusion. Complete metabolic response, partial response and unresolved uptake call for different plans. Assign responsibility for any pending image review instead of leaving the patient to interpret it. [S3]
Record doxorubicin exposure and any cardiac abnormality, together with chest-radiation information when applicable. Symptoms, risk and previous findings determine whether later echocardiography or other tests are needed. New chest pain, orthopnea, swelling or persistent palpitations needs prompt medical review. [S3,S15]
Separate completed China charges from remaining follow-up services, then budget home tests and medicines through the local system. No individualized annual follow-up amount was verified here. Ask which remote consultations, image reviews or additional investigations are billed separately rather than assuming the initial package covers all future care. [S10]

Quick answer

Full guide

A home hematologist should accept the handover before travel, with access to the summary and original images. Confirm appointments, urgent care and any continuing bispecific, antiviral, transfusion or test requirements. Do not wait until medicines run out or fever develops to find a prescriber.

Bring back a precise response assessment

The summary should specify final pathology, baseline stage, actual regimen and doses, completion date, final imaging and the response conclusion. Complete metabolic response, partial response and unresolved uptake call for different plans. Assign responsibility for any pending image review instead of leaving the patient to interpret it. [S3]

Retain pretreatment and final DICOM images. Later clinicians may need to compare original sites, residual structure and metabolism. A one-page discharge certificate may be insufficient for a new biopsy or radiation decision. If progression is already established, the return plan is continuing-treatment coordination rather than routine surveillance.

Name the clinician responsible for each part

Hematology oversees lymphoma assessment, while primary care can help with chronic disease and general prevention. Cardiology, infection, rehabilitation or fertility services may be added when appropriate. Remote advice from China can support care, but local emergency and prescribing responsibility must be assigned to clinicians able to see the patient. [S12]

Document contact routes, record transfer and expected response arrangements. Messages about stable issues cannot replace acute assessment. If several doctors prescribe, identify who reconciles the list so that prevention is not duplicated, stopped early or left without renewal. The patient should not be the sole coordinator.

Tailor review frequency to the current situation

Early after treatment, closer clinical review may be appropriate, followed by adjustments according to control and recovery. The home team should create the calendar rather than copying another patient's interval. Recent CAR T cells, transplantation or ongoing medication requires different follow-up from uncomplicated recovery after standard immunochemotherapy. [S3]

At the first home visit, review symptoms, activity, weight, counts, organ function and medicine-specific monitoring. For a recovering abnormality, specify the next test and action criteria rather than only booking a distant routine appointment. Mild fatigue does not automatically require a complete new staging work-up.

Understand why frequent routine PET may not help

End-of-treatment PET has a role in response assessment, but repeated PET in an asymptomatic patient in remission should not be automatic. Inflammation can create findings that lead to further procedures and anxiety. NICE and EHA follow-up approaches support clinically selected assessment rather than treating scan frequency as a measure of care quality. [S2,S3]

Report a persistent new mass, unexplained fever, marked sweats, weight loss or progressive local symptoms. Targeted imaging or biopsy may then be appropriate. One normal scan does not guarantee no future relapse, and one abnormal scan does not prove it. Symptoms and earlier images remain part of interpretation.

Continue the agreed infection-prevention plan

B-cell-directed treatment, CAR T cells and transplantation can affect immunity after ordinary counts improve. Do not independently stop all prevention once the white count looks normal. Antiviral treatment for hepatitis B and other prevention or immune support should be reviewed according to the actual risk and specialist plan. [S3,S11,S13]

Take generic names, purposes, review dates and stopping criteria home. If a product is unavailable locally, both teams should arrange an appropriate alternative before departure. Fever of 38°C or above, especially with chills, breathlessness or mental change, requires local assessment rather than waiting for an email reply. [S8]

Reassess vaccination and further travel

Vaccine timing depends on medicines, immune recovery and infection risk. Live vaccines require particular caution during substantial immunosuppression. After transplantation or CAR T cells, a dedicated schedule may be necessary. CDC guidance provides relevant considerations, but the individual plan belongs to the treating specialists. [S14]

Returning home does not automatically make another long journey suitable. Significant anemia, thrombocytopenia, recurrent infection or frequent monitoring needs should prompt reassessment. [S22] Confirm medicines, documents and emergency access at the destination. A last-minute vaccine is not a substitute for evaluating overall travel fitness.

Track cardiac and nerve health through the exposure history

Record doxorubicin exposure and any cardiac abnormality, together with chest-radiation information when applicable. Symptoms, risk and previous findings determine whether later echocardiography or other tests are needed. New chest pain, orthopnea, swelling or persistent palpitations needs prompt medical review. [S3,S15]

Numbness, pain, instability and impaired fine movement may require rehabilitation or medication. Persistent neuropathy is not automatically relapse, but new or progressive focal weakness needs investigation. Document when symptoms began and earlier dose changes so the home clinician can assess their course.

Include the additional long-term needs after CAR T cells

Follow persistent cytopenias, infections, immune recovery and other late problems, keeping the product and infusion date available. Transfer earlier cytokine release syndrome or neurotoxicity and its management. A long interval since infusion does not justify dismissing every new neurological or systemic symptom without assessment. [S11]

NCI discusses secondary T-cell malignancies after CAR T treatment, supporting continued long-term observation. [S23] FDA removal of some REMS requirements did not remove important labeled risks. [S19] The actual review and reporting responsibilities should follow the product and center's plan rather than a self-designed surveillance program.

Distinguish blood-count recovery from post-transplant recovery

After autologous transplantation, hematologic and immune recovery can follow different schedules. Infection, organs and nutrition still need attention. Allogeneic transplantation adds graft-versus-host and immunosuppression issues and should not be confused with autologous care. The home clinician must know the type and current medicines. [S13]

Confirm access to transfusions, fluids or antimicrobial services if these were recently needed. New rash, persistent diarrhea, jaundice, fever or other symptoms should be handled through the individual transplant plan. A routine health check cannot automatically replace experienced specialist follow-up.

Rebuild activity, nutrition and work gradually

Anemia, sleep, nutrition, mood and organ effects can limit strength after treatment. Develop a gradual activity plan with the clinician or rehabilitation service rather than immediately resuming the full previous workload. Neuropathy, heart or lung problems and significant cytopenias may require particular restrictions. [S12]

Persistent appetite loss or falling weight warrants nutrition support matched to mouth, swallowing, nausea or bowel symptoms. [S21] Recovery does not require expensive supplements or broad food prohibitions. Practical help with tasks and respect for the recovery pace can be more useful than repeated instructions to remain positive.

Arrange fertility and emotional support when needed

Future pregnancy planning should consider medicines, age and reproductive function, with specialist referral when appropriate. Return of menstruation or one normal laboratory result does not answer every fertility and safety question. Retain records of stored sperm, eggs or embryos. [S9]

Fear of relapse and disturbed sleep around scans can persist after treatment. Seek support if anxiety or low mood substantially affects life. Agreeing on symptoms that should trigger contact can create more stability than adding unlimited scans. Families should also respect how much detail the patient wants to discuss.

Do not treat ongoing therapy as ordinary remission follow-up

A bispecific, another continuing medicine or research regimen can require scheduled doses and safety tests. Confirm frequency, stop rules, supply and toxicity contacts before returning. [S6,S7] A missed or delayed dose requires instructions rather than independent compensation or restarting.

Trials have specific imaging, laboratory and reporting requirements, including possible follow-up after dosing stops. The study team must accept which tests can be done locally. [S17] Use the agreed channel and retain dates and originals. Ending an overseas stay does not automatically end study responsibilities.

Clarify costs and appointments before departure

Separate completed China charges from remaining follow-up services, then budget home tests and medicines through the local system. No individualized annual follow-up amount was verified here. Ask which remote consultations, image reviews or additional investigations are billed separately rather than assuming the initial package covers all future care. [S10]

Finally check the accepting doctor, first appointment, medicine supply, emergency location and record backups. Uncertain imaging, persistent low counts or uncontrolled infection requires an explicit monitoring plan before travel. The home clinician needs actionable instructions, not only the phrase regular follow-up.

Use the first home appointment to confirm that the handover is operational. Check that the images can be opened, the pharmacy recognizes the medicines, the next tests are booked and the emergency route is usable. Assign a person and date to any missing item instead of making the patient repeatedly retell the entire course. After a major medicine change or new response assessment, update the one-page summary and share it with the clinicians who need it. Keeping a clearly identified current version can prevent different services from acting on an old prescription or an already-resolved concern.